A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

What Was Tested

In this phase 2 trial, researchers set out to test Eloralintide.

The study will last about 64 weeks and may include up to 17 visits.

It had seven arms (groups): Placebo (placebo comparator), one (experimental), one (experimental), one (experimental) and one (experimental).

Participants received subcutaneous (SC) injections of eloralintide-matching placebo administered once weekly (QW) for 48 weeks.

The registry classes the interventions as drug.

Who Took Part

The registry lists 263 actual participants took part.

It was open to people of any sex aged from 18 years up to 75 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Are males and females who agree to abide by the reproductive and contraceptive requirements. Have a body mass index (BMI). ≥30 kilogram/square meter (kg/m²), or. ≥27 kg/m² and \<30 kg/m², or with at least 1 weight-related comorbidity.

The full record lists 5 inclusion and 14 exclusion criteria; among the exclusions: have any prior diagnosis of diabetes mellitus except gestational diabetes; have any of the following cardiovascular conditions within 6 months prior to screening:; acute myocardial infarction.

How the Study Was Run

Design: randomized, parallel-group and double-blind.

Random assignment meant chance, not the researchers, decided who got Eloralintide and who got the comparison, which limits bias.

The Eloralintide group and the comparison group ran side by side rather than switching.

Blinding on both sides kept the participants and researchers unaware of who received Eloralintide.

Those kept unaware of assignments: participant and investigator.

It started in 2024-02-05 with completion listed for 2025-05-30.

It ran at 43 sites in United States (43).

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Percent Change From Baseline in Body Weight at Week 48 (time frame: Baseline, Week 48).

It also tracked 6 secondary outcomes, for example Change From Baseline in Body Weight at Week 48, Change From Baseline in Body Mass Index (BMI) at Week 48 and PK: Maximum Concentration (Cmax) of Eloralintide at Steady State.

What This Means in Plain Language

Put simply, this is a phase 2, randomized trial of Eloralintide in 263 people.

The trial is marked completed; results are posted on the registry, and this page does not restate them.

More context: the Eloralintide compound page, all human trials.